Rockley Photonics Holdings Limited signed supply agreement outlining the customer's initial purchase commitment for 2023 and received the first commercial purchase order for its non-invasive biomarker sensing wristbands from a global healthcare technology provider. The Bioptx™ Baseline devices included in this order will employ Rockley's biosensing technology, a complete end-to-end solution that enables the non-invasive, continuous, and near-real-time monitoring of multiple biomarkers. The initial units are expected to ship in Fourth Quarter 2022, which could put Rockley's ground-breaking biosensing technology on the wrists of end-users by the end of 2022.

The Rockley Bioptx band represents a new class of wearable biosensing devices, with enhanced health monitoring capabilities and a flexible design that's appropriate for a multitude of applications and uses, such as professional healthcare or general health and wellness. The form and function of the device allow it to be worn on the wrist or other locations on the body, depending on the use case and physical requirements. In addition to a versatile form factor, the Bioptx band features a flexible hardware design that will support a range of software stacks that can be customized to address the specific needs of various customers.

The software can be further adjusted to optimize battery life for extended use or maximize performance for intensive duty cycles.